MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1

Molecular and Cellular Biology

Volumn 34, Issue 22, 2014, Pages 4143-4164

  Sharma, Sriganesh B ^a   Lin, Chen Chung ^a   Farrugia, Mark K ^a   McLaughlin, Sarah L ^a   Ellis, Emily J ^a   Brundage, Kathleen M ^a   Salkeni, Mohamad A ^a,b   Ruppert, J Michael ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 206; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPTIDES AND PROTEINS; RAS P21 PROTEIN ACTIVATOR (GTPASE ACTIVATING PROTEIN) 1; RAS PROTEIN; SPROUTY RELATED EVH1 DOMAIN CONTAINING PROTEIN 1; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; KRUPPEL LIKE FACTOR; MEMBRANE PROTEIN; MIRN206 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; RASA1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SPRED1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST; BREAST TUMOR; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICRORNAS; P120 GTPASE ACTIVATING PROTEIN; PROTEIN BIOSYNTHESIS; RAS PROTEINS;

EID: 84908879686     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00480-14     Document Type: Article

References (98)

1. Weinberg RA. 2007. Growth factors, receptors, and cancer, p 119-158. In Weinberg RA (ed), The biology of cancer. Garland Science, Taylor and Francis Group, LLC, New York, NY.
2. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912. http://dx.doi.org/10.1126/science.1072682.
3. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11-22. http://dx.doi.org/10.1038/nrc969.
4. Kolch W. 2005. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6:827-837. http://dx.doi.org/10.1038/nrm1743.
5. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. 2006. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46:249-279. http://dx.doi.org/10.1016/j.advenzreg.2006.01.004.
6. Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. http://dx.doi.org/10.1038/sj.onc.1210422.
7. Mebratu Y, Tesfaigzi Y. 2009. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8:1168-1175. http://dx.doi.org/10.4161/cc.8.8.8147.
8. Young A, Lyons J, Miller AL, Phan VT, Alarcon IR, McCormick F. 2009. Ras signaling and therapies. Adv. Cancer Res. 102:1-17. http://dx.doi.org/10.1016/S0065-230X(09)02001-6.
9. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. 2011. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11:761-774. http://dx.doi.org/10.1038/nrc3106.
10. Boguski MS, McCormick F. 1993. Proteins regulating Ras and its relatives. Nature 366:643-654. http://dx.doi.org/10.1038/366643a0.
11. Yoshimura A. 2009. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J. Med. 58:73-83. http://dx.doi.org/10.2302/kjm.58.73.
12. Vigil D, Cherfils J, Rossman KL, Der CJ. 2010. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10:842-857. http://dx.doi.org/10.1038/nrc2960.
13. Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernandez H, Burlingame AL, McCormick F. 2012. A shared molecular mechanism underlies the human rasopathies Legius syndrome and neurofibromatosis-Genes Dev. 26: 1421-1426. http://dx.doi.org/10.1101/gad.190876.112.
14. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E. 2007. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet. 39:1120-1126. http://dx.doi.org/10.1038/ng2113.
15. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in develop mental disorders and cancer. Nat. Rev. Cancer 7:295-308. http://dx.doi.org/10.1038/nrc2109.
16. Tidyman WE, Rauen KA. 2009. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 19:230-236. http://dx.doi.org/10.1016/j.gde.2009.04.001.
17. Bos JL. 1989. RAS oncogenes in human cancer: a review. Cancer Res. 49:4682-4689.
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954. http://dx.doi.org/10.1038/nature00766.
19. Prior IA, Lewis PD, Mattos C. 2012. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72:2457-2467. http://dx.doi.org/10.1158/0008-5472.CAN-11-2612.
20. Garnett MJ, Marais R. 2004. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319. http://dx.doi.org/10.1016/j.ccr.2004.09.022.
21. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. 2002. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80:239-256. http://dx.doi.org/10.1016/S0960-0760(01)00189-3.
22. Whyte J, Bergin O, Bianchi A, McNally S, Martin F. 2009. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 11:209. http://dx.doi.org/10.1186/bcr2361.
23. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. 2009. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69:565-572. http://dx.doi.org/10.1158/0008-5472.CAN-08-3389.
24. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. 2009. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 15:4649-4664. http://dx.doi.org/10.1158/1078-0432.CCR-09-0317.
25. Prat A, Perou CM. 2011. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5:5-23. http://dx.doi.org/10.1016/j.molonc.2010.11.003.
26. van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FB, van't Veer LJ, Nederlof PM. 2005. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 65:822-827.
27. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8:R76. http://dx.doi.org/10.1186/gb-2007-8-5-r76.
28. Rakha EA, Reis-Filho JS, Ellis IO. 2008. Basal-like breast cancer: a critical review. J. Clin. Oncol. 26:2568-2581. http://dx.doi.org/10.1200/JCO.2007.13.1748.
29. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G. 2009. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 7:511-522. http://dx.doi.org/10.1158/1541-7786.MCR-08-0107.
30. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70. http://dx.doi.org/10.1038/nature11412.
31. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL. 2012. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18:1052-1059. http://dx.doi.org/10.1038/nm.2795.
32. Gysin S, Salt M, Young A, McCormick F. 2011. Therapeutic strategies for targeting ras proteins. Genes Cancer 2:359-372. http://dx.doi.org/10.1177/1947601911412376.
33. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL. 2012. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-321. http://dx.doi.org/10.1016/j.cell.2012.02.053.
34. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676. http://dx.doi.org/10.1016/j.cell.2006.07.024.
35. Rowland BD, Peeper DS. 2006. KLF4, p21 and context-dependent opposing forces in cancer. Nat. Rev. Cancer 6:11-23. http://dx.doi.org/10.1038/nrc1780.
36. McConnell BB, Yang VW. 2010. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev. 90:1337-1381. http://dx.doi.org/10.1152/physrev.00058.2009.
37. Ghaleb AM, McConnell BB, Nandan MO, Katz JP, Kaestner KH, Yang VW. 2007. Haploinsufficiency of Kruppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res. 67:7147-7154. http://dx.doi.org/10.1158/0008-5472.CAN-07-1302.
38. McCormick SM, Eskin SG, McIntire LV, Teng CL, Lu CM, Russell CG, Chittur KK. 2001. DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 98:8955-8960. http://dx.doi.org/10.1073/pnas.171259298.
39. Yoon HS, Chen X, Yang VW. 2003. Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J. Biol. Chem. 278:2101-2105. http://dx.doi.org/10.1074/jbc.M211027200.
40. Pedersen TX, Leethanakul C, Patel V, Mitola D, Lund LR, Dano K, Johnsen M, Gutkind JS, Bugge TH. 2003. Laser capture microdissectionbased in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene 22:3964-3976. http://dx.doi.org/10.1038/sj.onc.1206614.
41. Liu Y, Sinha S, McDonald OG, Shang Y, Hoofnagle MH, Owens GK. 2005. Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J. Biol. Chem. 280:9719-9727. http://dx.doi.org/10.1074/jbc.M412862200.
42. Liu Y, Wang J, Yi Y, Zhang H, Liu J, Liu M, Yuan C, Tang D, Benjamin IJ, Xiao X. 2006. Induction of KLF4 in response to heat stress. Cell Stress Chaperones 11:379-389. http://dx.doi.org/10.1379/CSC-210.1.
43. Ghaleb AM, Katz JP, Kaestner KH, Du JX, Yang VW. 2007. Kruppellike factor 4 exhibits antiapoptotic activity following gamma-radiationinduced DNA damage. Oncogene 26:2365-2373. http://dx.doi.org/10.1038/sj.onc.1210022.
44. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK. 2007. Kruppel-like factor 4 regulates endothelial inflammation. J. Biol. Chem. 282:13769-13779. http://dx.doi.org/10.1074/jbc.M700078200.
45. Liao X, Haldar SM, Lu Y, Jeyaraj D, Paruchuri K, Nahori M, Cui Y, Kaestner KH, Jain MK. 2010. Kruppel-like factor 4 regulates pressureinduced cardiac hypertrophy. J. Mol. Cell. Cardiol. 49:334-338. http://dx.doi.org/10.1016/j.yjmcc.2010.04.008.
46. Lai JK, Wu HC, Shen YC, Hsieh HY, Yang SY, Chang CC. 2012. Kruppel-like factor 4 is involved in cell scattering induced by hepatocyte growth factor. J. Cell Sci. 125:4853-4864. http://dx.doi.org/10.1242/jcs.108910.
47. Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, Hayes MR, Broker TR, Chow LT, Ruppert JM. 1999. Oncogene expression cloning by retroviral transduction of adenovirus E1Aimmortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ. 10:423-434.
48. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM. 2005. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 24:1491-1500. http://dx.doi.org/10.1038/sj.onc.1208307.
49. Rowland BD, Bernards R, Peeper DS. 2005. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a contextdependent oncogene. Nat. Cell Biol. 7:1074-1082. http://dx.doi.org/10.1038/ncb1314.
50. Leng Z, Tao K, Xia Q, Tan J, Yue Z, Chen J, Xi H, Li J, Zheng H. 2013. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cellenriched spheroid cells. PLoS One 8:e56082. http://dx.doi.org/10.1371/journal.pone.0056082.
51. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, Lobuglio AF, Lobo-Ruppert SM, Ruppert JM. 2004. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin. Cancer Res. 10:2709-2719. http://dx.doi.org/10.1158/1078-0432.CCR-03-0484.
52. Chu PY, Hsu NC, Liao AT, Yeh KT, Hou MF, Liu CH. 2011. Elevated Kruppel-like factor 4 transcription factor in canine mammary carcinoma. BMC Vet. Res. 7:58. http://dx.doi.org/10.1186/1746-6148-7-58.
53. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Karesen R, Shama PK, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB. 2011. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol. Oncol. 5:77-92. http://dx.doi.org/10.1016/j.molonc.2010.11.002.
54. Chen CJ, Lin SE, Lin YM, Lin SH, Chen DR, Chen CL. 2012. Association of expression of Kruppel-like factor 4 and Kruppel-like factor 5 with the clinical manifestations of breast cancer. Pathol. Oncol. Res. 18:161-168. http://dx.doi.org/10.1007/s12253-011-9422-7.
55. Lin CC, Liu LZ, Addison JB, Ivanov AV, Ruppert JM. 2011. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Mol. Cell. Biol. 31:2513-2527. http://dx.doi.org/10.1128/MCB.01189-10.
56. Lee YS, Dutta A. 2009. MicroRNAs in cancer. Annu. Rev. Pathol. 4:199-227. http://dx.doi.org/10.1146/annurev.pathol.4.110807.092222.
57. Kasinski AL, Slack FJ. 2011. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11:849-864. http://dx.doi.org/10.1038/nrc3166.
58. Iorio MV, Croce CM. 2012. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4:143-159. http://dx.doi.org/10.1002/emmm.201100209.
59. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065-7070. http://dx.doi.org/10.1158/0008-5472.CAN-05-1783.
60. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658. http://dx.doi.org/10.1053/j.gastro.2007.05.022.
61. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980-984. http://dx.doi.org/10.1038/nature07511.
62. Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, Yan L, Malhotra A, Vatner D, Abdellatif M. 2008. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 19:3272-3282. http://dx.doi.org/10.1091/mbc.E08-02-0159.
63. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. 2008. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128-2136. http://dx.doi.org/10.1038/sj.onc.1210856.
64. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. 2009. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37:2584-2595. http://dx.doi.org/10.1093/nar/gkp117.
65. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN. 2010. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18:282-293. http://dx.doi.org/10.1016/j.ccr.2010.08.013.
66. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406-3415. http://dx.doi.org/10.1093/nar/gkg595.
67. Mathelier A, Zhao X, Zhang AW, Parcy F, Worsley-Hunt R, Arenillas DJ, Buchman S, Chen CY, Chou A, Ienasescu H, Lim J, Shyr C, Tan G, Zhou M, Lenhard B, Sandelin A, Wasserman WW. 2014. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res. 42:D142-D147. http://dx.doi.org/10.1093/nar/gkt997.
68. Boyd KE, Farnham PJ. 1999. Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol. Cell. Biol. 19: 8393-8399.
69. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686-1690. http://dx.doi.org/10.1093/nar/23.10.1686.
70. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW. 2000. The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J. Biol. Chem. 275:18391-18398. http://dx.doi.org/10.1074/jbc.C000062200.
71. Geiman DE, Han TT, Johnson JM, Yang VW. 2000. Transactivation and growth suppression by the gut-enriched Krüppel-like factor (Krüppel-like factor 4) are dependent on acidic amino acid residues and protein-protein interaction. Nucleic Acids Res. 28:1106-1113. http://dx.doi.org/10.1093/nar/28.5.1106.
72. Evans PM, Zhang W, Chen X, Yang J, Bhakat KK, Liu C. 2007. Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation. J. Biol. Chem. 282:33994-34002 http://dx.doi.org/10.1074/jbc.M701847200.
73. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE. 2000. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60:6890-6894.
74. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. 2005. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol. 19:1740-1751. http://dx.doi.org/10.1210/me.2004-0011.
75. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20. http://dx.doi.org/10.1016/j.cell.2004.12.035.
76. Fukazawa H, Noguchi K, Murakami Y, Uehara Y. 2002. Mitogenactivated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol. Cancer Ther. 1:303-309.
77. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, Van de Vijver MJ, Reis-Filho JS. 2010. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013-2023. http://dx.doi.org/10.1038/onc.2009.489.
78. Infante JR, Papadopoulos KP, Bendell JC, Patnaik A, Burris HA, Rasco D, III, Jones SF, Smith L, Cox DS, Durante M, Bellew KM, Park JJ, Le NT, Tolcher AW. 2013. A phase 1b study of trametinib, an oral mitogenactivated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur. J. Cancer 49:2077-2085. http://dx.doi.org/10.1016/j.ejca.2013.03.020.
79. Britten CD. 2013. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 71: 1395-1409. http://dx.doi.org/10.1007/s00280-013-2121-1.
80. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. 2008. miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res. 68:5004-5008. http://dx.doi.org/10.1158/0008-5472.CAN-08-0180.
81. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR, Olson EN. 2009. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326:1549-1554. http://dx.doi.org/10.1126/science.1181046.
82. Dey BK, Gagan J, Dutta A. 2011. miR-206 and-486 induce myoblast differentiation by downregulating Pax7. Mol. Cell. Biol. 31:203-214. http://dx.doi.org/10.1128/MCB.01009-10.
83. Liu N, Williams AH, Maxeiner JM, Bezprozvannaya S, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN. 2012. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J. Clin. Invest. 122:2054-2065. http://dx.doi.org/10.1172/JCI62656.
84. Guttilla IK, White BA. 2009. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 284: 23204-23216. http://dx.doi.org/10.1074/jbc.M109.031427.
85. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, Iba H. 2008. miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol. 378:492-504. http://dx.doi.org/10.1016/j.jmb.2008.03.015.
86. Armstrong JA, Bieker JJ, Emerson BM. 1998. A SWI/SNF-related chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell 95:93-104. http://dx.doi.org/10.1016/S0092-8674(00)81785-7.
87. Kadam S, Emerson BM. 2003. Transcriptional specificity of human SWI/SNF BRG1 andBRMchromatin remodeling complexes. Mol. Cell 11:377-389. http://dx.doi.org/10.1016/S1097-2765(03)00034-0.
88. Wu JI, Lessard J, Crabtree GR. 2009. Understanding the words of chromatin regulation. Cell 136:200-206. http://dx.doi.org/10.1016/j.cell.2009.01.009.
89. Gaspar-Maia A, Alajem A, Meshorer E, Ramalho-Santos M. 2011. Open chromatin in pluripotency and reprogramming. Nat. Rev. Mol. Cell Biol. 12:36-47. http://dx.doi.org/10.1038/nrm3036.
90. Clark GJ, Quilliam LA, Hisaka MM, Der CJ. 1993. Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein. Proc. Natl. Acad. Sci. U. S. A. 90:4887-4891. http://dx.doi.org/10.1073/pnas.90.11.4887.
91. Huang DC, Marshall CJ, Hancock JF. 1993. Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol. Cell. Biol. 13:2420-2431.
92. Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A. 2001. Spred is a Sprouty-related suppressor of Ras signalling. Nature 412:647-651. http://dx.doi.org/10.1038/35088082.
93. Fotiadou PP, Takahashi C, Rajabi HN, Ewen ME. 2007. Wild-type NRas and KRas perform distinct functions during transformation. Mol. Cell. Biol. 27:6742-6755. http://dx.doi.org/10.1128/MCB.00234-07.
94. Jeng HH, Taylor LJ, Bar-Sagi D. 2012. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. 3:1168. http://dx.doi.org/10.1038/ncomms2173.
95. Young A, Lou D, McCormick F. 2013. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3:112-123. http://dx.doi.org/10.1158/2159-8290.CD-12-0231.
96. Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D. 2014. Wild-type H-and N-ras promote mutant K-ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25:243-256. http://dx.doi.org/10.1016/j.ccr.2014.01.005.
97. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG. 2012. DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 40:W498-W504. http://dx.doi.org/10.1093/nar/gks494.
98. Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, Chuang EY. 2012. miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS One 7:e42390. http://dx.doi.org/10.1371/journal.pone.0042390.